Background. Uraemic bone disease is the result of a number of factors modulating bone formation and resorption in a complex manner. In the present study, the hypothesis tested was that the type of haemodialysis membrane used for renal replacement therapy might also play a role. Methods. We conducted a prospective, open study in 24 chronic haemodialysis patients who were randomized to dialysis treatment with either cellulosic (CELL group, ns11) or polyacrylonitrile (AN-69 group, ns13) membrane for 9 months. Repeated determinations of plasma parameters re¯ecting bone turnover were done in all patients, and a bone biopsy in a subgroup at the start and end of study. Results. At the start, mean plasma intact parathyroid hormone levels were comparable between the two groups and they did not vary signi®cantly at 9 months of treatment. Similarly, plasma bone-speci®c alkaline phosphatase and osteocalcin (markers of bone formation), and cross-laps (marker of bone resorption) remained unchanged. However, plasma insulin-like growth factor-I (IGF-I) progressively decreased from 169 to 119 nguml in AN-69 group (P-0.01), whereas it remained unchanged in CELL group. In addition, the levels of IGF binding protein (IGFBP)-1 and IGFBP-2 were increased while the levels of IGFBP-5 were decreased in AN-69 group. In the ®ve patients of each group who had repeat bone biopsies, histomorphometric analysis showed a decrease in osteoblast surface, osteoclast surface and osteoclast number in AN-69 group at 9 months, compared with baseline values measured at the start of the study. In contrast, all three parameters signi®cantly increased in the CELL group at 9 months (P-0.001 for the difference between each of the three parameters).Bone formation rate decreased by 31% in the AN-69 group, but increased by 50% in CELL group. However, this latter difference was not statistically signi®cant. Plasma interleukin (IL)-6 and soluble IL-6 receptor levels did not change in the two groups of patients who had undergone bone biopsy. Conclusion. Dialysis with CELL membrane was associated with increased bone turnover whereas the use of AN-69 membrane was associated with decreased bone turnover, suggesting a bene®cial effect of the latter on high-turnover uraemic bone disease. However, as the number of patients with repeat bone biopsies was small, these ®ndings need to be con®rmed in a larger study. Further studies are also needed to evaluate whether or not the changes in IGF system components play a role in decreased bone cell activity in patients on dialysis using the AN-69 polyacrylonitrile membrane.
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Introduction
Chronic renal failure patients may suffer from various osteo-articular problems such as osteitis ®brosa, mixed bone lesions, osteomalacia, adynamic bone disease, or dialysis-associated arthropathy. A number of factors are involved in these complications, including impaired calcium intake and absorption, phosphate retention, vitamin D de®ciency, secondary hyperparathyroidism, hypoparathyroidism, aluminium overload, secondary oxalosis, and b2-microglobulin amyloidosis. Speci®c types of underlying nephropathy may contribute to renal osteopathy, as for instance diabetes mellitus and primary oxalosis.
Last but not least, some treatments given to uraemic patients exert marked effects on the skeleton such as corticosteroids and immunosuppressive drugs. Renal replacement therapy is part of such treatment-related factors. Thus, a low calcium concentration of the dialysis¯uid may lead to a stimulation of parathyroid hormone (PTH) release during and after the dialysis whereas a high calcium concentration inhibits PTH secretion. The bacteriologic quality of the dialysate has been suggested to play a role in the occurrence of carpal tunnel syndrome, probably via endotoxin release and excessive cytokine generation, and the type of haemodialysis membrane has also been shown to in¯uence the prevalence of carpal tunnel syndrome and destructive arthropathy in chronic dialysis patients w1x.
In contrast, not much is known about a possible contribution to uraemic osteodystrophy of the dialysis procedure and, in particular, the type of haemodialysis membrane used for renal replacement therapy. Therefore, we decided some years ago to test this hypothesis in a retrospective study. We found evidence of higher bone turnover in patients on long-term haemodialysis treatment with cellulosic membranes (Cuprophan) than in patients dialysed with highly permeable, synthetic membranes (polyacrylonitrile AN-69 or high-¯ux polysulfone) for prolonged time periods w2x. Additional indirect evidence in favour of a possible contribution of the dialysis technique to bone complications is the observation of an association between plasma cytokine levels, known to be modi®ed by the dialysis procedure, and bone cell activity in uraemic patients w3x.
The goal of the present prospective, randomized study in chronic haemodialysis patients was to con®rm our hypothesis, based on retrospective and indirect evidence, that the use of a relatively biocompatible, highly permeable synthetic dialysis membrane should be associated with a lower bone turnover than the use of a less biocompatible, low permeability cellulosic membrane. For this purpose, patients with comparable degrees of mild to moderate hyperparathyroidism were allocated to a 9-month treatment period with either cellulosic or polyacrylonitrile AN-69 membrane. Possible changes of their bone metabolism during this time period were evaluated by circulating bone markers, and a subgroup of patients also underwent repeat bone histomorphometric examination and detailed analysis of circulating IGF system components.
Patients and methods

Study protocol
The initial plan of our study was to recruit a total number of 40 haemodialysis patients with mild to moderate degrees of hyperparathyroidism. Two dialysis centres agreed to participate, one located in Lisbon, Portugal and the other in Amiens, France. Inclusion criteria were: stable haemodialysis treatment 3 3 4±5 h per week with cellulosic membrane (cellulose acetate or cellulose diacetate) for at least 6 months, normal plasma calcium, pre-dialysis plasma phosphorus between 1.3 and 2.0 mmolul, plasma intact PTH (iPTH) between 100 and 500 pguml (normal 10±65 pguml), dialysate calcium between 1.5 and 1.75 mmolul, and bicarbonate as the dialysis¯uid buffer. Exclusion criteria were: presence of in¯ammatory syndrome, diabetes mellitus or other systemic diseases, introduction or change of dose of calcium or vitamin D supplements for last 6 months, glucocorticoid administration, and dialyser reuse. All medications had to be kept stable during entire study period.
Twenty patients of each centre were randomly assigned to one of two treatment arms, the goal being to have comparable initial plasma iPTH values in each group. A step-by-step procedure was used, allocating randomly the ®rst pair of patients with the highest baseline plasma iPTH to either arm, then the second pair with the next lower iPTH values and so on until the pair with the lowest iPTH values was reached. Unfortunately, the number of patients in the two centres who ful®lled the criterion of baseline iPTH values between 100 and 500 pguml and who agreed to participate at study was too small, so that the range of iPTH values had to be enlarged secondarily to values comprised between 16 and 1265 pguml.
The two treatment arms consisted of haemodialysis treatment for a period of 9 months either with cellulosic membrane (cellulose acetate or cellulose diacetate, CELL group) or with polyacrylonitrile AN-69 membrane (AN-69 group), under otherwise stably maintained dialysis conditions.
All the patients underwent bimonthly local monitoring of plasma total calcium, phosphorus, total protein, iPTH and total alkaline phosphatases. In addition, plasma samples were taken and stored at the start and at time points 6 and 9 months of study (and also at 12 months in Lisbon centre) for subsequent determinations of iPTH, bone-speci®c alkaline phosphatase, osteocalcin, total and free insulin-like growth factor-I (IGF-I), IGF-II, IGF binding protein (IGFBP)-1 to -6, and cross-laps concentrations. Plasma interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6R) levels were determined at the start and at time points 6, 9, and 12 months.
In addition, the patients of the Lisbon centre underwent a bone biopsy immediately before the start of study and again at the end of study, which is within a maximum of 2 months after the 9-month treatment period.
Participating patients
In the Amiens centre, 14 Caucasian chronic haemodialysis patients of the initially recruited 20 subjects completed the study, six in the CELL group and eight in the AN-69 group. Among the ®ve patients who left the study prematurely: one died, one moved to another centre and three received kidney grafts. The baseline dialysis treatment schedule during the 6 months prior to study was 3 3 4±5 h per week. Oral calcium carbonate supplements were prescribed to the majority of patients in the Amiens centre and the dose was maintained stable unless serum phosphorus increased. Alfacalcidol therapy of 0.25 mguday or less was given to two patients and maintained stable throughout the 9 month-study period. The dialysate calcium concentration was 1.5 mmolul in all patients.
In the Lisbon centre, only a total of 10 patients completed the study, ®ve in the CELL group and ®ve in the AN-69 group. It was actually impossible to obtain a total number of 20 patients with repeat bone biopsies at a 9 month interval. Sixteen patients were initially recruited. Six left prematurely: three received kidney transplants, two were transferred to another centre, and one died of myocardial infarction. The baseline dialysis treatment schedule during the 6 months prior to study was 3 3 4 h per week. The dialysate calcium concentration was 1.5 mmolul in all patients. Calcitriol therapy of 0.25 mguday or less was given to one patient and this dose was maintained throughout the 9 month study period. Oral calcium carbonate supplements were prescribed to the majority of the patients and the dose was maintained stable in all of them throughout the study.
Assays
All blood samples were non-fasting morning samples. Plasma total calcium, phosphorous, total alkaline phosphatase, albumin, C-reactive protein (CRP), and transferrin were determined by standard biochemical methods.
Plasma iPTH levels were measured using an immunoradiometric assay (Nichols Institute Diagnostics, Paris, France), with normal values comprised between 10 and 65 pguml and intra-and inter-assay coef®cients of variation of less than 7%.
To assess bone metabolism more speci®cally, bone-speci®c alkaline phosphatase (bAP; Hybritech, Ko È ln, Germany) and osteocalcin (CIS, Dreieich, Germany) were determined by RIA. For quanti®cation of degradation products of C-terminal telopeptides of type I collagen, plasma crosslaps were determined by Cross-laps One Step Elisa kit (Osteometer BioTech, Herlev, Denmark). In a personal study, plasma cross-laps levels were determined in 140 healthy men and 140 healthy women with normal renal function, aged 60±80 years. The range of values found in these individuals was 1.25±5.40 nmolul for men and 1.35±7.40 nmolul for women (unpublished results). In addition, they were also determined in healthy pre-menopausal women aged 40±50 years. In these women, the levels were lower, in the range of 0.65±2.85 nmolul (unpublished results). Circulating IL-6 and sIL-6R were determined using commercially available kits (Biosource International, CliniSciences, Montrouge, Paris).
Plasma total IGF-I was measured with a new IRMA kit (IGF-I RIACT, Cis Bio, Gif sur Yvette, France), using two monoclonal antibodies directed against two different epitopes of the IGF-I molecule. No extraction step was performed, but the bound IGF-I was displaced from IGFBPs by acidi®cation. An excess IGF-II was then added to the acid-treated serum to prevent re-association of IGF-I with its carrier proteins when buffer was added. In our laboratory, the within-run CV (SDumean of 10 measurements of three serum pools) was 1.8% at 52 nguml, 3.7% at 289 nguml, and 4.1% at 676 nguml, while the between-run CV (the same three serum pools measured in duplicate over six non-consecutive days) was 5.8% at 56 nguml, 4.5% at 299 nguml, and 4.1% at 700 nguml. The detection limit, de®ned as the concentration at the meanq3SD of 20 measurements of the zero calibrator, was 1 nguml. Serial dilutions of eight sera with high (three acromegalic patients) or medium (®ve patients with renal failure on haemodialysis) IGF I concentrations gave recovery values of 89.2±104.5%.
All the other components of the circulating IGF system were measured as previously described w4x. Free IGF-I levels were determined by a speci®c RIA (DSL, Frankfurt, Germany) with intra-and inter-assay coef®cients of variation of less than 11%. There was no cross-reaction with IGF-II, insulin, proinsulin, and growth hormone. IGF-II was measured by a speci®c RIA (DSL, Frankfurt, Germany) with intra-and inter-assay coef®cients of variation of less than 7.5 and 10.5%. There was no cross-reaction with IGF-I, insulin, proinsulin, and IGFBP-2, -3, -4, and -5. IGFBP-1 was measured by enzyme immunoassay (ELISA, Mediagnost, Tuebingen, Germany) with intra-and inter-assay coef®cients of variation of less than 4 and 8% and no cross-reaction with other IGFBPs. IGFBP-2 was measured by a speci®c RIA with intra-and inter-assay coef®cients of variation of less than 9 and 8% and no cross-reaction with IGFBP-1, -3, -4, -5, and -6 (DSL, Frankfurt, Germany). IGFBP-3 was determined by a speci®c RIA with intra-and inter-assay coef®cients of variation of less than 3.5 and 7.5% and no cross-reaction with other IGFBPs (Mediagnost, Tuebingen, Germany). IGFBP-4 and -5 were measured by speci®c RIA as previously described (see Ref. w3x) with intra-and interassay coef®cients of variation of less than 10% and no crossreaction with other IGFBPs. IGFBP-6 was determined by a speci®c RIA with intra-and inter-assay coef®cients of variation of less than 11 and 10% and no cross-reaction with IGFBP-1, -2, -3, -4 and -5 (DSL, Frankfurt, Germany).
Bone biopsy and bone histomorphometry
Two transiliac bone biopsies, using the trephine of BordierMeunier with an internal diameter of 8 mm, were obtained in all Lisbon patients, one at the start of study and the other after 9±12 months, and analysed as reported previously w2x. For bone tetracyclin labelling, patients ®rst received an oral dose of 250 mg doxytetracyclin twice daily for 3 days, then stopped taking tetracyclin for 10 days, and then resumed tetracyclin for another 3 days. Bone biopsy was performed 5 days after the last dose. 
Statistical evaluation
Statistics were computed using SPSS. Results have been expressed as mean"SEM. Data were analysed by Student's paired or unpaired t test and one-way analysis of variance (ANOVA), followed by Newman±Keuls test. The analysis was separated for the individual subgroups. Correlations between variables (Pearson's correlation coef®cient) were assessed using univariate linear regression analysis. P-0.05 was accepted as statistically signi®cant.
Results
Baseline clinical and biochemical data
The baseline clinical and biochemical data of the 24 patients from Amiens and Lisbon centres combined and of the 10 patients from Lisbon centre alone are summarized in Table 1 . The patients of the two centres and within the groups were comparable with respect to age, gender, and duration of haemodialysis time. On average, the patients of the Lisbon centre had biochemical evidence of higher bone formation (bone-speci®c alkaline phosphatase, osteocalcin) and bone resorption (cross-laps) rates than the patients of the Amiens centre. Plasma total IGF-I levels were comparable between the patients of the two centres. Of note, inter-individual differences of total IGF-I levels were less marked than those of the circulating bone markers. In the Lisbon centre patients, plasma albumin, CRP, and transferrin levels were comparable between AN-69 and CELL groups: 3.86"0.103 vs 3.62"0.100 gudl for albumin, PsNS; 7.4"1.4 vs 6.5"0.5 mgul for CRP, PsNS; and 179"13 vs 171"17 mgudl for transferrin, PsNS).
Biochemical markers of bone metabolism
As shown in Table 2 , plasma total calcium and phosphorus levels were stable and comparable in all groups throughout the three time periods of study. Moreover, no signi®cant changes in circulating bonespeci®c markers were observed between both groups. At baseline, iPTH levels were comparable between AN-69 group and CELL group patients and did not signi®cantly change during the follow-up period of 9 months. Similarly, plasma concentrations of bone-speci®c alkaline phosphatase, osteocalcin, and cross-laps remained unchanged during this observation period.
IGF system components
In the AN-69 group, plasma IGF-I levels progressively decreased whereas no change was found in the CELL group (Table 2 and Figure 1 ). The differing behaviour of plasma IGF-I levels with time between AN-69 and CELL groups observed in the whole patient group was also seen when considering the Lisbon group patients alone, namely a decrease in total IGF-I levels in AN-69-treated patients, but no change in CELLtreated patients (Figure 2 ). Table 3 summarizes data on circulating IGF system components in the ®ve AN-69-group patients and the ®ve CELL-group patients of the Lisbon centre, compared with reference values of healthy control subjects. Similar to total IGF-I concentrations, AN-69 patients revealed a moderate decrease in free IGF-I levels reaching signi®cance at 6 months. In contrast with the total and free IGF-I levels, IGF-II levels remained unchanged in both groups. To address the question whether changes in the different IGFBPs may account for the¯uctuations in free and total IGF-I levels in the AN-69 but not in the CELL groups, we further determined IGFBP-1 to -6 levels by speci®c immunoassays. Interestingly, in AN-69 patients plasma levels of IGFBP-1 increased continuously, reaching 2-fold higher levels after 12 months compared with baseline values. Furthermore, IGFBP-2 levels were moderately higher at 12 months whereas IGFBP-5 levels decreased with a nadir at 9 months (1.7-fold lower levels, P-0.05). In contrast, in CELL-treated patients, levels of IGFBP-1 remained unchanged but those of IGFBP-5 signi®cantly increased, with a maximum of 1.6-fold value at 9 months (P-0.05).
No correlation was found between plasma iPTH and IGF-I levels at baseline or during study for all patients together. Similarly, no correlation existed between plasma iPTH and any of the other IGF system components in Lisbon group patients (data not shown).
Cytokine and in¯ammatory parameters
No differences between groups were observed in the change with time of plasma cytokine parameters IL-6 and sIL-6R in the patients of the Lisbon centre except a slightly, signi®cantly (P-0.05) lower IL-6 level in AN-69-group patients than in CELL group patients at the 12 months time point. Plasma IL-6 levels for the 0, 6, 9-and 12-month study time points were 6.6"1.0, 5.9"1.4, 8.3"3.0, and 7.2"0.5 pguml in AN-69 group, .0"9.9 nguml in CELL group, respectively. Of interest, when comparing all available plasma levels from Lisbon centre patients at all time points (ns40), a signi®cant correlation was found between the plasma levels of sIL-6R and those of osteocalcin (rs0.54, P-0.001), of bone-speci®c alkaline phosphatase (rs0.60, P-0.002), and of cross-laps (rs0.48, P-0.002).
Bone histomorphometry
At the start of the study, the mean values of the three static parameters of bone formation and bone resorption measured in the 10 patients of the Lisbon centre were elevated compared with values in healthy subjects: osteoblast surface (Ob.SuBS, ns10), 12.4"3.2%; osteoclast surface (Oc.SuBS; ns10), 7.0"2.3%; osteoclast number (N.Oc; ns10), 3.34"0.75umm 2 . At the 9 months time point, the values of these bone formation and resorption parameters had signi®cantly decreased in AN-69 group patients compared with baseline; in contrast, same values had signi®cantly increased in CELL group patients. Figure 2 shows the increase and decrease of the three parameters in the former and the latter group, respectively. Dynamic parameters of bone turnover in these patients are shown in Table 4 . Mean MAR and BFR values decreased in AN-69 group by 17 and 31%, respectively, whereas mean MS did not change. In Table 2 . Plasma markers of bone turnover of all AN-69 group and all CELL group patients (Amiens and Lisbon centres combined), and of Lisbon centre patients alone at start (T 0 ) and end (T 9mo. ) of study (mean"SEM) contrast, in the CELL group mean BFR and MS values increased by 50 and 48%; however, MAR remained unchanged. Although several of these changes were marked, none of them reached the level of statistical signi®cance, presumably because of the small sample size. Finally, Figure 3 shows a positive correlation between BFR and plasma IGFBP-5, and a negative correlation with IGFBP-4 at the start of study, when taking the values of all patients together. Similar positive and negative relations, respectively, were found with MAR and MS (data not shown).
Discussion
The major ®nding of this prospective study was an increase in bone cell number and activity in patients haemodialysed with CELL membrane whereas a decrease was observed in patients dialysed with polyacrylonitrile AN-69 membrane. This ®nding was based on repeat bone histomorphometry. Similar trends were also observed for dynamic parameters of bone turnover, with decreases in mean MAR and BFR in the AN-69 group, but increases in mean MS and BFR in the CELL group; however, these opposite changes did not reach the level of signi®cance. These observations were made in the absence of signi®cant changes of plasma intact PTH. As the mean starting plasma iPTH levels in both patient groups of our study were only modestly elevated and mean bone formation rate was only moderately elevated, this may have made the effects of different dialysis treatments more dif®cult to determine. Nonetheless, it is noteworthy that the improvement of skeletal activity in association with the synthetic, highly permeable dialysis membrane Fig. 2 . Absolute changes (mean"SE) of bone formation and bone resorption parameters after treatment with either AN-69 polyacrylonitrile (AN-69) or diacetate cellulose (CELL) dialysis membranes, respectively, in patients of Lisbon centre at time point 9 months (second bone biopsy), compared with baseline values at 0 month (®rst bone biopsy). Osteoblast surface (Obl. SuBS), ns5 and 5, respectively; osteoclast surface (Ocl. SuBS), ns5 and 5, respectively; osteoclast number (Ocl. nr), ns5 and 5, respectively. Table 3 . IGF system components (reference values) in AN-69 group (ns5 patients) and CELL group (ns5 patients) of Lisbon centre from start to end of study (mean"SEM; *P-0.05, **P-0.01 vs T 0mo ) brought about a return to the upper range of normal, whereas the use of cellulosic membrane led to an aggravation of skeletal turnover. The present study con®rms our previous hypothesis, based on ®nd-ings made in a retrospective study, of an association between bone turnover and type of dialysis membrane w2x.
AN-69 group
The second important ®nding of this study was the progressive decrease of total and free plasma IGF-I concentrations in the AN-69 patient group whereas no signi®cant change occurred in the CELL group. This latter observation is in keeping with the well-known role of IGF-I in the modulation of bone turnover, in that high IGF-I levels stimulate bone formation whereas low levels are associated with a reduction of bone turnover w4x. It remains to be established whether the changes in serum levels of IGFBPs are the cause or consequence of the decrease in IGF-I levels in AN-69 group patients. Both IGFBP-1 and -2 are known to inhibit IGF-I action w6x whereas IGFBP-5 plays a key role in regulating bone formation w7x. Clinical studies in patients with metabolic bone diseases revealed that IGFBP-1 and -2 levels are negatively, but IGFBP-5 levels positively correlated with bone mineral density and histological indices of bone formation w4,8x. Our ®nding of a positive correlation between bone formation rate and plasma IGFBP-5, and a negative relation between bone formation rate and plasma IGFBP-4 in all Lisbon patients together is in agreement with these reports. Of note, no correlation was found between plasma iPTH and any of the IGF system components.
Our observations raise a number of intriguing questions. The ®rst is why there were no concomittant changes of circulating markers considered to re¯ect bone activity (except the above mentioned changes of IGF system components). One would have expected the same directional changes of these markers as the ones indicated by histomorphometrically assessed bone parameters. One possibility is that circulating markers are less reliable than bone biopsy ®ndings to assess changes of bone turnover in individual patients. This is particularly true in the case of normal or low bone turnover w9x. Another possibility is the small number and the low degree of homogeneity of the present patient population at the start of the study. This, together with the relatively weak sensitivity of available bone turnover markers in the circulation, may have prevented us from observing signi®cant differences when in fact changes of moderate degree did occur. A third possibility is that whereas plasma markers are thought to re¯ect the average turnover of the entire skeleton bone biopsy can only inform, strictly speaking, about the focal condition at the site of bone tissue sampling. As bone biopsy usually provides better information about spongious bone than about cortical bone, one could speculate that the observed differences in osteoblast and osteoclast numbers and surface between the two groups of patients mainly re¯ect differences in spongious bone.
We also failed to observe a change of the plasma cytokine IL-6 or its circulating receptor sIL-6R. IL-6, which is produced by osteoblasts, is an established Table 4 . Dynamic parameters of bone turnover in AN69 group (ns5) and CELL (ns5) group patients of Lisbon centre at start (T 0mo. ) and end (T 9mo. ) of study (mean"SEM, PsNS) factor of osteoclast activation, independent of the OPGuOPG-L (osteoprotegerin and osteoprotegerinligand) system w10x. In our patients, IL-6 was only correlated with CRP (data not shown), indicating its implication in the in¯ammatory state of uraemia. However, sIL-6R was correlated with markers of bone formation (bAP and osteocalcin) and bone resorption (cross-laps), which is in favour of a role in uraemic osteodystrophy. Circulating levels of cytokines probably do not re¯ect well the situation at the bone tissue level. The stimulation of other cytokines by cellulosic dialysis membranes, but not by synthetic membranes, and the subsequent interference with cellular and subcellular processes involving the skeletal action of PTH, vitamin D and other hormones and cytokines is also possible. The second question is why plasma total IGF-I concentrations decreased with highly biocompatible AN-69 membrane, but not with less biocompatible CELL membrane. As the AN-69 membrane is known to adsorb numerous plasma proteins onto its surface, in contrast to cellulosic membrane w11x, it is possible that circulating IGF-I is regularly removed during dialysis sessions with the former, but not the latter type of membrane. The results of a recent study appear to plead against such a possibility as no acute change of plasma IGF-1 concentration were observed during a dialysis session with AN-69 membrane w11x. Moreover, plasma IGF-1 is not necessarily modi®ed by other types of biocompatible membranes. Thus, in a previous study aimed at examining the long-term effect of membrane biocompatibility on nutritional parameters, no difference in pre-dialysis serum total IGF-I values was observed between two groups of chronic haemodialysis patients treated for 18 months with either cellulosic membrane or polymethylmethacrylate (PMMA) membrane w12x. However, the physical properties and biocompatibility characteristics of the latter are different from those of AN-69 membrane. Another possibility would be an aggravation in the nutritional status of our patients treated with AN-69 membrane, compared with CELL membrane. However, there was no clinical or biochemical evidence in support of this theory. In contrast, highly biocompatible membranes have been recently shown to offer an advantage over cellulosic membranes in terms of morbidity and mortality w13±15x.
The third question is what may be the relative importance of the IGF system, compared with other endocrine systems such as the PTH±vitamin D axis, for the metabolic activity of the skeleton in uraemic patients. In case of severe secondary hyperparathyroidism, high bone turnover is mainly a result of this cause and associated conditions such as insuf®cient calcium intake and vitamin D de®ciency. However, at present parathyroid overfunction is generally better controlled than 10±20 years ago, and other factors may come into play which were previously less important or simply neglected. Thus, it has become clear that bone turnover is regulated by numerous factors other than calcium, phosphate, PTH, and vitamin D. The role of numerous growth factors and cytokines in the regulation of bone metabolism has been progressively elucidated during recent years. Disturbances of the activity of several of these factors may play a role in uraemic bone disease as well w16x. To what extent such disturbances may be re¯ected by changes in circulating concentrations of such factors or only by local changes in concentration or activity, remains to be seen. The IGF system is one of them, and changes of circulating IGF and IGFBPs such as plasma IGFBP-4 and IGFBP-5 have been shown to be associated with abnormal bone turnover in uremia w4,17x. Thus, total and free IGF-I was lower in haemodialysis patients with osteopenia than in those without osteopenia w4x, in accord with other studies in osteoporosis patients without renal failure w8, 18,19x . Recently, Garnero et al. reported that in 435 healthy post-menopausal women decreased serum concentrations of IGF-I were strongly associated with an increased risk of osteoporotic fractures independently of bone mineral density w20x. In this study, however, serum IGF-I concentrations explained less than 6% of the inter-individual variance of bone mineral density at any skeletal sites. Studies in smaller groups of renal failure patients found no relationship between IGF-I levels and bone metabolism. Coen et al. failed to identify a correlation between plasma IGF-I levels and bone formation parameters in pre-dialysis patients w21x. In dialysis patients, Weinreich et al. were unable to ®nd a difference in plasma IGF-I, IGF-II, IGFBP-2, or IGFBP-3 levels between two groups having either severe secondary hyperparathyroidism or adynamic bone disease w22x. The con¯icting results of the links between serum IGF-I and bone metabolism could be because of different underlying metabolic diseases such as diabetes or obesity and differences in nutritional status w23, 24x. It remains to be determined whether IGFBP-5 is a more sensitive bone marker than IGF-I concentrations.
In conclusion, dialysis with CELL membrane was associated with stimulation of bone turnover whereas the use of AN-69 membrane slowed down bone cell activity, suggesting a bene®cial effect of the latter on uraemic bone disease. However, the issue whether the observed association between the decrease in plasma IGF-I and the reduction of histologic parameters of bone formation and resorption is causal or coincidental requires further study. Moreover, the results of the present work need to be con®rmed in a larger patient population.
